How much is Areteia Therapeutics worth in 2026?

Areteia Therapeutics has a current valuation of N/A based on their Early Stage VC round and secondary market data.

How much funding has Areteia Therapeutics raised?

Areteia Therapeutics has raised $425.0M in total funding across 1 funding rounds.

Areteia Therapeutics

Drug DiscoveryWebsite

Areteia Therapeutics valuation and funding history | Last updated: May 1, 2025 | 1 funding rounds

Current Valuation

N/A

As of May 1, 2025

Total Funding Raised

$425.0M

Across 1 round

Last Round

Early Stage VC

$425.0M

Last Funding

May 2025

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
February 12, 2024	Early Stage VC (Series A1)	$425.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Areteia Therapeutics is currently valued at N/A as of May 1, 2025. The company has raised a total of $425.0M in funding across 1 funding round.

Track Areteia Therapeutics Valuation Updates

Get notified when Areteia Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Areteia Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Areteia Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Areteia Therapeutics Worth in 2026?

Areteia Therapeutics is a leading private company in the Drug Discovery sector. Track Areteia Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Areteia Therapeutics Valuation is Determined

Private company valuations like Areteia Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.